Past Issue

Volume 14, Number 1, Apr-Jun 2020 Pages: 23-26

Effect of Single-Dose Methotrexate Treatment on Ovarian Reserve in Women with Ectopic Pregnancy Undergoing Infertility Treatment: A Single-Center Experience

Mahboobeh Shirazi, M.D, 1, 2, Parichehr Pooransari, M.D, 3, Neda Hajiha, M.D, 2, Zeinab Shaker, M.D, 1, Mohadeseh Ghazi, M.D, 2, Fatemeh Davari Tanha, M.D, 1, Batool Ghorbani Yekta, Ph.D, 4, 5, Marjan Ghaemi, M.D, 1, 6, *,
Maternal, Fetal and Neonatal Research Center, Tehran, Iran
Breast Feeding Research Center, Tehran University of Medical Sciences, Tehran, Iran
Shohada Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Young Researchers and Ethics Club, Tehran Medical Science Branch, Islamic Azad University, Tehran, Iran
Herbal Pharmacology Research Center, Tehran Medical Science Branch, Islamic Azad University, Tehran, Iran
Kamali Hospital, Alborz University of Medical Sciences, Karaj, Iran
*Corresponding Address: P.O.Box: 14146 Maternal Fetal and Neonatal Research Center Tehran Iran



The aim of this study was evaluation of the impact of single-dose methotrexate (MTX) treatment on ovarian reserve in women with ectopic pregnancy (EP) undergoing infertility treatment in Iranian population.

Materials and Methods

This prospective cohort study was done between March 2015 and March 2017 in Tehran General Women Hospital, Tehran, Iran. We enrolled 20 patients with EP who conceived during infertility treatment and received a single-dose MTX (50 mg/m2) intramuscularly. Serum anti-Mullerian hormone (AMH), 17 beta-estra diol (E2), luteinizing hormone (LH), follicle-stimulating hormone (FSH) and antral follicle count (AFC) on transvaginal ultrasonography, were evaluated before and 8 weeks after administration of MTX.


AMH did not significantly vary after the administration of MTX, compared to before treatment value (P=0.36). FSH, E2 and AFC changes were not statistically significant, while increment of LH was significant (P=0.02).


Results indicated that single-dose MTX treatment did not reduce ovarian reserve in women with EP. Further randomized controlled clinical trial studies with larger sample sizes, by using multiple dosages of MTX, and with long-term follow up are suggested to be done.